Download PDF
Thromb Haemost 1976; 35(01): 261-263
DOI: 10.1055/s-0038-1647951
Original Article
Schattauer GmbH

XXI Annual Meeting of the International Committee on Thrombosis and Haemostasis

K. M Brinkhous
Further Information

Publication History

Publication Date:
02 July 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Deutsch E, Brinkhous K. M, Lechner K, Hinnom S. eds. 1974; Thrombosis: Pathogenesis and Clinical Trials. Thrombosis et Diathesis Haemorrhagica Suppi 59 p. 352.
    PubMedSearch in Google Scholar
  • 2 Koller F. The physiological function of heparin. p. 17.
    PubMed
  • 3 Kiss J. Chemistry of heparin — a short review on recent chemical trends. p. 20.
    PubMed
  • 4 Estes J. W, Poulin P. F. Pharmacokinetics of heparin - distribution and elimination. p. 26.
    PubMed
  • 5 Abildgaard U. Heparin cofactor and antithrombin. p. 38.
    PubMed
  • 6 Yin E. T. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-2-globulin inhibitor. p. 43.
    PubMed
  • 7 Rosenberg R. D. The effect of heparin on factor XIa and plasmin. p. 51.
    PubMed
  • 8 Zucker M. B. Effect of heparin on platelet function. p. 63.
    PubMed
  • 9 Lüscher E. F, Kaser-Glanzmann R. Platelet heparin-neutralizing factor platelet factor. 4 p. 66.
    PubMed
  • 10 Markwardt F. Antilipemic action of heparin. p. 73.
    PubMed
  • 11 Godal H. C. Heparin assay methods for control of in vivo heparin effects. p. 77.
    PubMed
  • 12 Wessler S. Small doses of heparin and a new concept of hypercoagulability. p. 81.
    PubMed
  • 13 Kakkar V. V. Low dose heparin in the prevention of venous thromboembolism. Rationale and results. p. 87.
    PubMed
  • 14 McNicol G. P. Conventional uses of heparin. p. 97.
    PubMed
  • 15 Nyman D, Thurnherr N, Duckert F. Heparin dosage in extracorporeal circulation and its neutralization. p. 102.
    PubMed
  • 16 Lasch H. G, Heene D. H. Heparin therapy of diffuse intravascular coagulation DIC. p. 105.
    PubMed
  • 17 Straub P. W. A case against heparin therapy of intravascular coagulation. p. 107.
    PubMed
  • 18 Saliba M. J, Saliba R. J. Heparin in burns - dose related and dose dependent effects. p. 113.
    PubMed
  • 19 Brinkhous K. M. XX annual meeting of the International Committee on Thrombosis and Haemostasis. p. 124.
    PubMed
  • 20 Blombäck B. Report of the Subcommittee on Nomenclature. p. 126.
    PubMed
  • 21 Abildgaard U. Report of the Task Force on Inhibitors of Blood Coagulation. p. 127.
    PubMed
  • 22 Blombäck B. Report of the Task Force on Nomenclature of Fibrinogen-Fibrin Degradation Products. p. 141.
    PubMed
  • 23 Ménaché D. Report of the Task Force on Clinical Use of factor IX Concentrates. p. 597.
    PubMed
  • 24 Ménaché D. Factor IX concentrates. p. 600.
    PubMed
  • 25 Hoofnagle J. H, Aronson D, Roberts H. Serologic evidence for hepatitis B virus infection in patients with hemophilia B - a multicenter study. p. 606.
    PubMed
  • 26 Roberts H. R, Blatt P. M. Post-transfusion hepatitis following the use of prothrombin complex concentrates. p. 610.
    PubMed
  • 27 Kingdon H. S, Lundblad R. L, Veltkamp J. J, Aronson D. L. Potentially thrombogenic materials in factor IX concentrates. p. 617.
    PubMed
  • 28 Cash J. D, Dalton R. G, Middleton S, Smith J. K. Studies on the thrombo-genicity of Scottish factor IX concentrates in dogs. p. 632.
    PubMed
  • 29 Kasper C. K. Thromboembolic complications. p. 642.
    PubMed
  • 30 Ménaché D, Roberts H. R. Summary report and recommendations of the Task Force members and consultants. p. 645.
    PubMed
  • 31 Day H. J, Holmsen H, Zucker M. B. Methods for separating platelets from plasma. p. 648.
    PubMed
  • 32 Verstraete M. Registry of prospective clinical trials. p. 655.
    PubMed